US45845P1084 - Common Stock
sNDA intended to satisfy post-marketing requirements to confirm a clinical benefit in patients with PBCPrecedent-setting submission includes data from...
BOLOGNA, Italy and MORRISTOWN, N.J., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Alfasigma S.p.A. (“Alfasigma”) and Intercept Pharmaceuticals, Inc. (“Intercept”)...
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
/PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential...
Overbought stocks are an early indication of a potential correction on a stock; act now if you hold these stocks.
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
ntercept Pharmaceuticals quickly dropped 3% amid a new report from the European Medicines Agency.
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
/PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential...
Intercept Pharmaceuticals' failure in developing Ocaliva for NASH led to an acquisition as its best outcome. Read more here.
Canaccord downgraded Intercept Pharmaceuticals to hold, calling its merger deal with Alfasigma for $19 per share the best outcome for the company. Read more here.
Intercept Pharmaceutical is unlikely to attract other bidders after agreeing to a $19 per share sale to Alfasigma, according to analysts.
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
Intercept is on track to be acquired by Alfasigma at a significant premium compared to recent prices.
Although Intercept Pharmaceuticals popped higher on a buyout deal, many stakeholders of ICPT stock are left wondering what might have been.
/PRNewswire/ -- Ademi LLP is investigating Intercept (Nasdaq: ICPT) for possible breaches of fiduciary duty and other violations of law in its transaction with...
Proposed all-cash acquisition will materially expand Alfasigma’s portfolio in gastroenterology and hepatology and its presence in the U.S....
The momentum continues after CymaBay reported great clinical results on Thursday.